Arrowstreet Capital
TAK icon

Arrowstreet Capital’s Takeda Pharmaceutical TAK Stock Holding History

Arrowstreet Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.8M Buy
3,732,924
+616,613
+20% +$10.2M 0.03% 500
2026
Q1 		$57.7M Sell
3,116,311
-2,566,536
-45% -$45M 0.03% 454
2025
Q4 		$88.6M Buy
5,682,847
+2,854,069
+101% +$40.8M 0.05% 315
2025
Q3 		$41.4M Buy
2,828,778
+1,610,088
+132% +$23.9M 0.03% 515
2025
Q2 		$18.8M Sell
1,218,690
-181,766
-13% -$2.69M 0.01% 706
2025
Q1 		$20.8M Sell
1,400,456
-2,815,917
-67% -$39.5M 0.02% 587
2024
Q4 		$55.8M Sell
4,216,373
-419,019
-9% -$5.76M 0.04% 348
2024
Q3 		$459K Buy
4,635,392
+2,319,877
+100% +$32.9M ﹤0.01% 1528
2024
Q2 		$30M Buy
2,315,515
+950,588
+70% +$12.6M 0.03% 390
2024
Q1 		$19M Sell
1,364,927
-543,294
-28% -$7.9M 0.02% 514
2023
Q4 		$27.2M Sell
1,908,221
-565,689
-23% -$8.03M 0.03% 364
2023
Q3 		$38.3M Buy
2,473,910
+139,715
+6% +$2.16M 0.05% 287
2023
Q2 		$36.7M Buy
2,334,195
+1,276,920
+121% +$20.9M 0.04% 295
2023
Q1 		$17.4M Sell
1,057,275
-2,847,021
-73% -$45.3M 0.02% 436
2022
Q4 		$60.9M Buy
3,904,296
+2,465,178
+171% +$34.4M 0.09% 212
2022
Q3 		$18.7M Buy
1,439,118
+406,032
+39% +$5.65M 0.03% 385
2022
Q2 		$14.5M Buy
1,033,086
+871,373
+539% +$12.4M 0.02% 430
2022
Q1 		$2.32M Buy
+161,713
New +$2.37M ﹤0.01% 779
2021
Q3 		– Sell
-87,700
Closed -$1.48M – 1854
2021
Q2 		$1.48M Sell
87,700
-173,431
-66% -$2.95M ﹤0.01% 1430
2021
Q1 		$4.77M Buy
261,131
+29,953
+13% +$539K 0.01% 1197
2020
Q4 		$4.21M Sell
231,178
-218,567
-49% -$3.83M 0.01% 1267
2020
Q3 		$8.02M Sell
449,745
-84,833
-16% -$1.54M 0.01% 945
2020
Q2 		$9.59M Buy
534,578
+119,577
+29% +$2.15M 0.02% 789
2020
Q1 		$6.3M Buy
415,001
+371,118
+846% +$6.73M 0.02% 654
2019
Q4 		$866K Buy
+43,883
New +$840K ﹤0.01% 1373
2019
Q2 		– Sell
-4,220,584
Closed -$86M – 1687
2019
Q1 		$86M Buy
4,220,584
+448,339
+12% +$9.02M 0.2% 110
2018
Q4 		$63.4M Buy
+3,772,245
New +$63.7M 0.17% 140

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Arrowstreet Capital's TAK Position: Q2 2026 in Review

Arrowstreet Capital increased its Takeda Pharmaceutical (TAK) stake by 20% in Q2 2026, buying an estimated $10.2M and bringing the position to 3,732,924 shares worth $59.8M. The position accounts for 0.03% of the portfolio, ranked #500.

Arrowstreet Capital first reported a position in TAK in Q4 2018 and has held it in 27 quarters since. The position peaked at $88.6M in Q4 2025. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Arrowstreet Capital held 3,732,924 shares of Takeda Pharmaceutical worth $59.8M as of Q2 2026.
  • Arrowstreet Capital bought 616,613 Takeda Pharmaceutical shares in Q2 2026, an estimated $10.2M.
  • Takeda Pharmaceutical made up 0.03% of Arrowstreet Capital's portfolio in Q2 2026, its #500 holding.
  • Arrowstreet Capital first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 27 quarters since.
  • Arrowstreet Capital's Takeda Pharmaceutical position peaked at $88.6M in Q4 2025.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.